ISSN: 2157-7013
Journal of Cell Science & Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Radiotherapy Approach in the Treatment of Mycosis Fungoides: Principles and Recommendations

Gustavo N Marta*, Samir A Hanna and João Luis F da Silva
Department of Radiotherapy, Sírio-Libanês, Oncology Center, São Paulo, Brazil
Corresponding Author : Gustavo N Marta
Department of Radiotherapy, Sírio- Libanês, Oncology Center
São Paulo, SP, Brazil
E-mail: gnmarta@uol.com.br
Received March 06, 2012; Accepted March 30, 2012; Published April 02, 2012
Citation: Marta GN, Hanna SA, da Silva JLF (2012) Radiotherapy Approach in the Treatment of Mycosis Fungoides: Principles and Recommendations. J Cell Sci Ther 3:119. doi: 10.4172/2157-7013.1000119
Copyright: © 2012 Marta GN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Cell Science & Therapy

Abstract

Background: Mycosis fungoides (T-cell non-Hodgkin’s lymphoma) is a quite rare neoplasia, which follows an indolent course, characterized by presenting epidermotropism in spite that there is a possibility of compromise of structures like lymph nodes and visceral organs. Its incidence increases starting from the fourth decade of life with posterior drop after more or less the age of 80, having preference for men. Objective: To analyze the role of radiotherapy in the therapeutic approach of patients with diagnosis of mycosis fungoides. Conclusions: Radiotherapy is indicated for patients suffering from mycosis fungoides in all stages especially when the disease has affected more than 50% of the body surface. Starting from stage IB, total skin irradiation is employed with a dose of 30 to 36 Gy with boost at medical criterion.

Introduction
Mycosis Fungoides (MF) (T-cell non-Hodgkin’s lymphoma) is a quite rare pathology that strikes approximately 1,400 individuals a year in the United States of America [1]. It incidence increases starting from the fourth decade of life with posterior drop after more or less the age of 80, having preference among black men [2-4].
Following an indolent course, the disease is characterized by presenting epidermotropism, in spite that there is a possibility of compromise of structures like lymph nodes and visceral organs [5,6]. Its etiology still remains uncertain and there is no real proof of the cause-effect relation with the following risk factors: cytomegalovirus infection and HTLV-1 (Human T-lymphotropic virus type I) infection, smoking, alcoholism and pesticide exposure and radiation [7-9]. The main prognostic factor is the disease staging (Table 1), [10] mainly in what refers to extent and type of involvement in the skin and the presence or absence of extracutaneous disease.
This study has the objective of demonstrating the role of radiotherapy in the therapeutic approach of patients with diagnosis of mycosis fungoides.
Recommendations of Treatment in Accordance with Staging
Stage IA
The treatment options for stage IA patients are topical chemotherapy (nitrogenated mustard or carmustine), [11] phototherapy, [12] topical corticotherapy, [13] local radiation (X-ray or electrons), [14] and topical retinoids [15].
MF is extremely sensitive to radiation. Low energy x-ray (100 kvp) can be applied in the treatment of isolated lesions although its use may be limited as a consequence of acute and late toxicity. Electron radiotherapy technique is the standard for the approach of these lesions. It presents complete response rate of 40 to 98%. The treatment margin is 2 cm with total dose of 15 to 25 Gy administered in 3 weeks. Generally it is indicated after treatment failure with nitrogenated mustard and topical corticoid [15].
Stage IB/IIA/IIB
For stages IB – IIB patients there are innumerous treatment forms that vary from radiotherapy of the entire skin with electrons (total skin irradiation – TSI), topical chemotherapy (nitrogenated mustard or carmustine), phototherapy (PUVA or UVB), topical corticoid up to systemic retinoids, interferon and systemic chemotherapy [16,17].
TSI has complete response rate of 80 – 97%. It can be employed as initial therapy in the presence of thick lesions for presenting greater therapeutic effect than topical chemotherapy and phototherapy. Normally it is used in patients with history of rapid disease progression or under the effect of treatment failure after initial topical approach [18-20].
Goujon et al. [21] in a retrospective study with 68 initial stage patients (30 stages T1; 38 stages T2) assessed the efficacy of TSI. The average time of treatment was six weeks and after three months from the end of therapy, 97% of patients had complete response. The global survival rates in five and 10 years were 86% and 71%, respectively. Thirty-nine patients (57.4%) had relapse with average disease free interval of 1.8 years. The disease-free survival was 41% and 31% for five and 10 years respectively, being greater when TSI was employed earlier (P = 0.003). After 21 years of follow-up, only one patient developed cutaneous neoplasia (basocellular carcinoma).
Ysebaert et al. [22] in a retrospective study included 141 stages T1 and T2 patients with MF that were treated with TSI. Of these, 25 patients received topical therapy prior to radiotherapy. Energy of 6 MeV was used with daily dose of 2 Gy (4 days/week) and total dose of 30 Gy. Three months after completion of treatment, 87.5% (T1) and 84.8% (T2) had complete response. Treatment failure in one year was 54.4%. From all those that had relapse (31 patients), 18 were submitted to a second course of TSI (24 Gy in 12 fractions) while the remaining 13, to other combined therapies. Local control in five years was greater in the group that received the second course of TSI (70% vs. 39%). For the entire group, the global survival in five, 10 and 15 years was 90%, 65% and 42%, respectively. In univariate analysis, T1 (P = 0.03), complete response after the first course of TSI (P = 0.04) and age under 60 years old (P < 0.001) were prognostic factors for global survival. In multivariate analysis, only patients with age under 60 years old had association with the increase of survival (P = 0.001).
Normally patient submitted to TSI tolerate well the treatment. Meanwhile, the large majority presents some type of side effect, being the most common: erythema, peeling skin with or with no ulceration, itch, alopecia, fall of nails, alteration in transpiration with hypohydrosis, edema of hands and feet. In spite that it is rare, cases of gynecomasty in men and epistaxis were already described. In long-term there can be appearance of telangectasia, permanent dystrophy of nails, partial alopecia and secondary squamoproliferative skin neoplasias. Due to low electron penetration, there is no gastrointestinal and hematological toxicity.
After three months from the conclusion of TSI, execution of phototherapy or topical chemotherapy with nitrogenated mustard can be considered as maintenance therapy.
Stage IIIA/IIIB/IV
In patients with advanced disease, introduction of more aggressive therapeutic measures becomes necessary. The treatment options (topical or systemic corticotherapy, topical or systemic chemotherapy, topical or systemic retinoids, phototherapy, chemotherapy, vorinostat, denileukin diftitox, bone marrow transplantation, TSI) vary depending on the characteristics of the presented lesions and on previously employed treatments [18].
In the palliative perspective where there is extensive or recurrent cutaneous and extra cutaneous disease after the first course of TSI there is possibility of repeat irradiation with new TSI plan with substantial benefits and acceptable toxicity rate.
Funk et al. [23] analyzed the efficacy of palliative TSI in 18 patients with advanced stage (stages IIb – V) cutaneous T-cell non-Hodgkin’s lymphoma refractory to previous treatments. The average applied total dose was 25 Gy with average follow-up of 11 months. Fifty percent of patients had complete response; 39%, partial response. The progression free survival in one year was 24% and the global survival in 1 year was 48%. All patients had acute side effects of mild to moderate intensity.
In a study conducted at Yale University (USA), [24] 14 patients received two courses of TSI while five patients, three courses. The median dose used in the first and second course was 36 Gy and 18 Gy respectively. Of the 5 patients who received a total of 3 courses, three received 12 Gy, one received 16 Gy and one received 30 Gy. After the first course of TSI, 93% had complete response; after the second, 86%, after the third, 60%. The median disease free interval after the first course of therapy for those with complete remission was 20 months and 11.5 months after the second course. All patients presented skinrelated side effects, with an acceptable risk profile.
Becker et al. [25] in a retrospective analysis studied 15 patients that received second course of TSI. The average dose employed in the first treatment was 32.6 Gy; in the second, 23.4 Gy; the complete and partial response rates after the second course were 40% and 60%, respectively. The observed late toxicity was restricted to drying of skin, telangectasia, alteration of cutaneous pigmentation and alopecia.
The criteria used for indication of repeat irradiation include the observed clinical response and the disease free interval after the first course of TSI, the area of cutaneous affectation and the prior failure of other therapeutic modes. Patients with nodal and/or visceral involvement are often benefitted with course of palliative TSI with total dose of 20 to 30 Gy (2 to 3 Gy/fraction).
Technical Aspects of Radiotherapy
There are diverse irradiation techniques in order to obtain an adequate dose distribution in the entire area to be treated. It is important to emphasize that in all of them dosimetry calculations are complex. Most services employ focus-skin distance (FSD) of approximately three to four meters. Habitually, the maximum distance that is achieved between the beam focus and the treatment table is lesser than two meters. Thus, it becomes necessary to use beams directed towards the lateral walls of the room in order to obtain an irradiation field of the order of 120 x 120 cm² on the treatment plane which allows coverage of large body surface area simultaneously. The extensive air layer to be crossed must be considered, since the beam energy spectrum is broadened, which can alter its penetration. Moreover, not all radiotherapy rooms were built with necessary minimum dimensions, since it is desirable for the patient to be at a distance of at least 1 meter from the wall to avoid possible backscatter contributions of the beam. It is important to stress that in these techniques, the patient stays standing up for a long period of time, being this, often, a limiting factor to its employment. One of the most classically used techniques is the “ballerina’s” technique (modified Stanford technique) [19] where six incidences of beams are used in the upper part and another six in the lower part of the body (separated by the bellybutton) making a total of twelve incidences. The patient is positioned on a rotating base that suffers rotations at every 60°.
As alternative, technique that uses lower FSDs (100 to 140 cm) so as to suppress the difficulties listed above. That is, in spite that, fields of area of the order of 30 x 30 cm² are used and, consequently, there is an increase of number of necessary incidences to cover the entire body surface, the treatment is performed with the patient lying down during the entire application not having any restrictions with respect to the dimensions of the room. Dose distribution in this technique is homogeneous as demonstrated by Martins [26] in a master’s degree dissertation of the Instituto de Física da Universidade de São Paulo.
The total prescription dose in the first course of treatment varies from 30 – 36 Gy with possibility of dose complement (boost) at medical criterion in the areas of subdosing and/or with tumor lesions. The patient is treated four days a week (two applications in the anterior region and two applications in the posterior region) with dose/fraction day of 200 cGy uninterruptedly. The duration of the treatment is from 10 to 11 weeks (36 sessions) in the first phase; if there is need of boost, this is executed in five to 10 more sessions on a daily basis (five times a week). The average period of every session is 60 minutes. In case there is need of repeat irradiation, the first is done with total dose of 20 Gy and the second, with 12 Gy using the same technique described above.
Conclusions
Radiotherapy is indicated to patients suffering from MF in all stages especially when the disease affects more than 50% of the body surface. Starting from stage IB, TSI is employed with dose of 30 to 36 Gy with boost at medical criterion. Consider phototherapy or topical chemotherapy with nitrogenated mustard as maintenance therapy after three months of TSI. Repeat irradiation is viable, however with treatment doses lower than those employed in the first therapeutic cycle.
Comprehensive Summary
• Indications for radiotherapy: Patients at all stages particularly when the disease affects more than 50% of body surface.
• Technical issue: Fields with direct energy of 6 MeV (electrons).
• Area of treatment: From stage IB, the entire body surface.
• Dose: 200 cGy on each side of the body 1000 cGy totaling in 10 days of treatment. Total dose of 3000 to 3600 cGy. Boost the physician’s criteria.
• Consider phototherapy or topical chemotherapy with nitrogen mustard after 3 months of TSI to maintenance therapy.
References
Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Adaptive Cell Therapy
Disc Adaptive Immunity
Disc Adipose Derived Stem Cells (ASCs)
Disc Advanced Cell Therapy
Disc Advances in Anatomy
Disc Advances in Embryology
Disc Allergy Immunology
Disc Antibody-Producing Cells
Disc Antigen-Presenting Cells
Disc Apoptotic Pathways
Disc Autologous Cell
Disc Autophagosomes
Disc Biomolecular Structure and Function
Disc Blood Cells
Disc Bone Marrow Cells
Disc Cancer Signaling Array
Disc Cancer Stem Cells (CSCs)
Disc Cell
Disc Cell Biology
Disc Cell Biology Junctions
Disc Cell Biology Techniques
Disc Cell Culture
Disc Cell Cycle
Disc Cell Death: Apoptosis
Disc Cell Receptors
Disc Cell Regeneration
Disc Cell Replacemnt Therapy
Disc Cell Signal
Disc Cell Signaling Mechanisms
Disc Cell Signaling Pathways
Disc Cell Therapy Bioprocessing
Disc Cell Therapy Products
Disc Cell motility
Disc Cell synthesis
Disc Cell tracking
Disc Cell-Biology
Disc Cellular Biology
Disc Cellular Communication
Disc Cellular DNA Studies
Disc Cellular Dynamics
Disc Cellular Immunology
Disc Cellular Ligands
Disc Cellular Oncogenes
Disc Cellular Signalling
Disc Cellular and Molecular Biology
Disc Centrioles
Disc Clinical Immunology
Disc Crynofacial Genetics
Disc Cytoskeleton
Disc DNA-based barcodings
Disc Dendritic Cell Therapy
Disc Dental Stem Cells
Disc Developmental Biology
Disc Diagnostic Immunology
Disc Embryonic Stem Cells (ESCs)
Disc EnteroEndocrine Cells
Disc Epithelial Cells
Disc Erythroid Cells
Disc Evolutionary Immunology
Disc Extracellular signaling
Disc Fetal Stem Cell Therapy
Disc Gene Expression and Regulation
Disc Germ Cells
Disc Germ cell tumours
Disc Hair Follicle Cells
Disc Hematology
Disc Hematopoietic Stem Cells (HSCs)
Disc Histology of Cell Biology
Disc Human Embryology
Disc Immune Cell Therapy
Disc Immuno Cell biology
Disc Inflammatory Disorders
Disc Intracellular Signaling
Disc Lipid Signaling Pathways
Disc Live Cell Therapy
Disc Mapk Pathway Cell Signaling
Disc Membrane Trafficking
Disc Mesenchymal Cells
Disc Mesenchymal Stem Cells
Disc Methods and Techniques in Molecular Biology
Disc Molecular Biochemistry
Disc Molecular Biotechnology
Disc Molecular Cell
Disc Molecular Genetics
Disc Molecular Signaling
Disc Multipotent Stem Cells
Disc Myeloid Stem Cells
Disc NO Signaling and Ion Channels
Disc Neural Stem Cells (NSCs)
Disc Neuroinflammatory Disorders
Disc Ocular Immunology and inflammation
Disc Ovation cell therapy
Disc Plant Cells
Disc Plant Stem Cells
Disc Pluripotent Stem Cells
Disc Polymerization
Disc Recombinant Cytokines
Disc Scaffold Signaling Proteins
Disc Signal Transduction
Disc Signal Transduction Cascades
Disc Signaling Systems
Disc Single Cell Analysis
Disc Single Cell Gene Expression
Disc Single Cell Genome
Disc Single Cell Protein
Disc Single cell Imaging
Disc Single cells
Disc Skin Cell Therapy
Disc Somatic Cell Therapy
Disc Stem Cell
Disc Stem Cell Biology
Disc Stem Cell Preservation
Disc Stem Cell Therapy for Diabetes
Disc Stem Cell Therapy for Osteoarthritis
Disc Stem Cell Transplant
Disc Stem Cells
Disc Tissue
Disc Totipotent Stem Cells
Disc Transcription
Disc Translational Immunology
Disc Transplantation Immunology
Disc Tumor Immunology
Disc Vaccine Immunology
Disc Viral Immunology
 
Recommended Journals
Disc Cell Signaling journal
Disc Cancer Research Journal
Disc Cell Science Journal
Disc Clinical and Laboratory Research Journal
Disc Clinical & Cellular Immunology Journal
Disc Molecular Biology Journal
Disc Cell Biology Journal
Disc Single Cell Biology Journal
Disc Stem Cell Research Journal
  View More»
 
Recommended Conferences
Disc 4th Plant Genomics
July 14-15, 2016 Brisbane, Australia
Disc 5th Tissue Science and Regenerative Medicine Conference
September 12-14, 2016 Berlin, Germany
Disc 3rd World Congress on Women’s Health and Breast Cancer

October 03-05, 2016 London, UK
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11134
  [From(publication date):
April-2012 - Jun 25, 2016]
  Breakdown by view type
  HTML page views : 7404
  PDF downloads :3730
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version